Management of Post-Viral Cough with Wheeze in Children

Introduction to Post-Viral Wheeze Management

The American Academy of Pediatrics provides a strong recommendation against administering albuterol or salbutamol to infants and children with bronchiolitis or post-viral respiratory symptoms (Evidence Quality: B) 1, 2
A Cochrane systematic review of 30 randomized controlled trials involving 1,992 infants found no benefit in oxygen saturation, disease resolution, need for hospitalization, or length of stay when bronchodilators were used 1, 2

At 19 months of age with a post-viral presentation, this represents viral-induced airway inflammation and mucus plugging, not reversible bronchospasm typical of asthma 1, 2
Children with viral wheeze are less likely to demonstrate airway hyperresponsiveness compared to those with asthma 4

Supportive care remains the mainstay: adequate hydration, nasal suctioning if needed, and monitoring for signs of respiratory distress 1, 2
Observation for worsening symptoms that might indicate progression to more severe disease requiring hospitalization 1
Parental education that post-viral cough can persist for 3-8 weeks and that the wheeze is due to airway inflammation, not bronchospasm 1

The American Thoracic Society recommends a trial of short-acting β2-agonists for infants and children born preterm (<37 weeks) with recurrent respiratory symptoms, as 55-75% may respond 4, 5
55% of infants with bronchopulmonary dysplasia (BPD) and recurrent wheeze respond to albuterol, compared to only 12.5% without wheezing 4
Children with established asthma, family history of atopy, or documented airway hyperresponsiveness may benefit from bronchodilators 4

Tachycardia and tremors are common adverse effects that can worsen the child's distress 1, 2
Cost and medicalization of a self-limited condition 1
False reassurance that may delay recognition of worsening disease 1